Leuprorelin acetate - Prostate cancer
You are here : Home > Formulary Search > Leuprorelin acetate - Prostate cancer
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Leuprorelin acetate
Indication :
Prostate cancer
Group Name :
Keywords :
Gonaderelin Analogue, Luteinising hormone-releasing hormone, LHRH agonist, PSDs, patient specific directions
Brand Names Include :
Prostap, Staladex
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Other Indications
Below are listed other indications that Leuprorelin acetate is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Prostate cancer.
Committee Recommendations (2)
01 Nov 17 -
Surrey Medicines Commissioners Group
Patient Specific Directions (PSDs) are often used to enable non-medical practitioners (practice nurses, health care assistants) to administer specific medicines for specific conditions.
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Prostap PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Prostap PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
Following harmonisation of the licensed indications for goserelin, leuprorelin and triptorelin, it was agreed by PCN that all three drugs should be available and will be considered Amber * on the traffic light system. The choice of product should be informed by an individual patient's preferences in relation to route of administration and frequency of injections.